Stock Track | Hims & Hers Health Soars 10.37% in Pre-market After Launching $49 Compounded Copy of Wegovy Weight-Loss Pill

Stock Track

Feb 05

Shares of Hims & Hers Health Inc. (HIMS) soared 10.37% during pre-market trading on Thursday, following a major business announcement from the telehealth company.

The significant price movement was driven by the company's announcement that it will begin offering compounded copies of Novo Nordisk's new Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount of approximately $100 compared to the brand-name version, which Novo Nordisk plans to charge $199 for.

Hims stated that its compounded product uses the same active ingredient, semaglutide, and can be tailored for patients. The company also highlighted that a recent facility expansion allows it to provide treatments at more accessible price points, positioning it competitively in the lucrative weight-loss drug market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1193407982"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193407982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193407982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 23:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193407982","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 10.37% in Pre-market After Launching $49 Compounded Copy of Wegovy Weight-Loss Pill","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) soared 10.37% during pre-market trading on Thursday, following a major business announcement from the telehealth company.</p><p>The significant price movement was driven by the company's announcement that it will begin offering compounded copies of Novo Nordisk's new Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount of approximately $100 compared to the brand-name version, which Novo Nordisk plans to charge $199 for.</p><p>Hims stated that its compounded product uses the same active ingredient, semaglutide, and can be tailored for patients. The company also highlighted that a recent facility expansion allows it to provide treatments at more accessible price points, positioning it competitively in the lucrative weight-loss drug market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 10.37% in Pre-market After Launching $49 Compounded Copy of Wegovy Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 10.37% in Pre-market After Launching $49 Compounded Copy of Wegovy Weight-Loss Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-05 23:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) soared 10.37% during pre-market trading on Thursday, following a major business announcement from the telehealth company.</p><p>The significant price movement was driven by the company's announcement that it will begin offering compounded copies of Novo Nordisk's new Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount of approximately $100 compared to the brand-name version, which Novo Nordisk plans to charge $199 for.</p><p>Hims stated that its compounded product uses the same active ingredient, semaglutide, and can be tailored for patients. The company also highlighted that a recent facility expansion allows it to provide treatments at more accessible price points, positioning it competitively in the lucrative weight-loss drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1193407982","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193407982","pubTimestamp":1770304954,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc. (HIMS) soared 10.37% during pre-market trading on Thursday, following a major business announcement from the telehealth company.The significant price movement was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪|Hims&Hers Health推出49美元复合版Wegovy减肥药盘前大涨10.37%","themeId":"c1153e9c0a8e9571f0041cca121599eb","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) soared 10.37% during pre-market trading on Thursday, following a major business announcement from the telehealth company.The significant price movement was driven by the company's announcement that it will begin offering compounded copies of Novo Nordisk's new Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount of approximately $100 compared to the brand-name version, which Novo Nordisk plans to charge $199 for.Hims stated that its compounded product uses the same active ingredient, semaglutide, and can be tailored for patients. The company also highlighted that a recent facility expansion allows it to provide treatments at more accessible price points, positioning it competitively in the lucrative weight-loss drug market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}